ArticleFrontiers in medicine2025
Untargeted metabolomics reveals distinct biomarkers and metabolic alterations in familial and non-genetic hypercholesterolemia in Saudi patients.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Familial hypercholesterolemia (FH) and non-genetic hypercholesterolemia (HC) are both associated with elevated low-density cholesterol (LDL-C) levels, which increase the risk of cardiovascular disease. However, their underlying metabolic disturbances differ significantly. Untargeted metabolomics offers a powerful approach for identifying disease-specific metabolic signatures and potential biomarkers, thereby contributing to precision medicine applications. Methods: A high-resolution metabolomics analysis was performed using ultra-performance liquid chromatography coupled with quadrupole time-of-flight mass spectrometry (UPLC-Q-TOF/MS) on plasma samples from FH, HC, and healthy Saudi individuals. Differentially expressed metabolites were identified through univariate and multivariate analyses, followed by pathway enrichment analysis using the KEGG database. Results: Metabolic profiling revealed distinct alterations in bile acid biosynthesis and steroid metabolism pathways in FH. Cholic acid was significantly downregulated, while 17α-hydroxyprogesterone (17α-OHP) was significantly elevated in FH. In contrast, HC was characterized by increased uric acid and choline levels, along with dysregulation in oleic acid and linoleic acid metabolism. Notably, both FH and HC groups were dysregulated in Sphinganine, D- Conclusion: This study demonstrates the utility of untargeted metabolomics in distinguishing FH from HC, identifying 17α-OHP and cholic acid as potential FH biomarkers, while uric acid and choline may serve as HC-specific metabolic markers. These findings provide new insights for personalized interventions, enhancing disease stratification and therapeutic decision-making between genetic and non-genetic hypercholesterolemia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.